Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transglutaminase 2 in inflammation.

Soo-Youl Kim1

  • 1Division of Basic Science, Research Institute, National Cancer Center, Goyang, Republic of Korea. kimsooyoul@gmail.com

Frontiers in Bioscience : a Journal and Virtual Library
|May 25, 2006
PubMed
Summary

Transglutaminase 2 (TG 2) enzyme activity increases NF-kappaB signaling by polymerizing I-kappaBalpha, independent of I-kappaBalpha kinase. Inhibiting TG 2 reverses this activation and inflammation, suggesting a new role for TG 2 in inflammatory processes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma.

Cancer research·2026
Same author

Transglutaminase 2 exacerbates ovarian cancer survival by directly inactivating GSK3β.

Cell death & disease·2026
Same author

Targeting the Primordial Chaperone to Overcome Acquired Drug Resistance in Cancer: TG2-Mediated Autophagy.

Biomolecules & therapeutics·2026
Same author

Pharmacological transglutaminase 2 inhibition enhances temozolomide response in patient-derived glioblastoma tumorspheres.

Journal of neuro-oncology·2026
Same author

Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs.

Cancer research·2025
Same author

Inhibiting Fatty Acid Oxidation Suppresses Acquired Resistance to Standard Chemotherapy in Melanoma.

International journal of molecular sciences·2025

Area of Science:

  • Biochemistry
  • Cell Biology
  • Immunology

Background:

  • Transglutaminase 2 (TG 2) expression is elevated in inflammatory diseases.
  • TG 2's precise role in inflammation remains unclear despite known physiological functions.
  • Aberrant TG 2 activity is linked to diseases like neurodegeneration, autoimmunity, and cancer, often via protein aggregation and apoptosis.

Purpose of the Study:

  • To elucidate the role of TG 2 in the inflammatory process.
  • To investigate the mechanism by which TG 2 influences NF-kappaB activation.
  • To explore TG 2 inhibition as a therapeutic strategy for inflammatory conditions.

Main Methods:

  • Investigated TG 2 activity and its effect on I-kappaBalpha and NF-kappaB signaling pathways in various cell lines.
  • Utilized TG 2 inhibitors to assess the reversal of NF-kappaB activation.
  • Evaluated the efficacy of TG 2 inhibitors in conjunctivitis models.

Main Results:

  • Increased TG 2 activity directly triggers NF-kappaB activation by polymerizing I-kappaBalpha, bypassing the I-kappaBalpha kinase pathway.
  • TG 2 inhibition effectively reverses NF-kappaB activation.
  • Treatment with TG 2 inhibitors led to the reversal of inflammation in experimental conjunctivitis models.

Conclusions:

  • TG 2 acts as a novel signal modulator in the inflammatory process.
  • TG 2-mediated I-kappaBalpha polymerization is a key mechanism for NF-kappaB activation.
  • TG 2 inhibitors show potential for treating inflammatory diseases by modulating this pathway.

Related Experiment Videos